"Maybe even this???"
I couldn't open that link gassed but I think I got an idea of what it's about from the link. There does seem to be a lot of activity by the big pharmas in the ADC area.
Not to be outdone by its Big Pharma peers, Johnson & Johnson has fattened up its antibody-drug conjugate (ADC) pipeline via the acquisition of Ambrx Biopharma for $2 billion.
Link to the article below. I would be happy with a $2b offer for PAB. It would equate to a share price of around Ninety cents US -
J&J beefs up ADC pipeline by acquiring Ambrx for $2B (fiercebiotech.com)
2024 An Eventful Year, page-3
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $43.28K | 6.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237374 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1732079 | 8 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |